We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B Turnover 24.14%
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+46.69%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.05B
AUM Growth
+$352M
Cap. Flow
-$16.5M
Cap. Flow %
-0.81%
Top 10 Hldgs %
43.96%
Holding
116
New
16
Increased
40
Reduced
31
Closed
12
Avg Time Held
2.7 years
Top 10 Avg Time Held
1 year
Top 20 Avg Time Held
1.8 years

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$31.1M
2
AVLN icon
Avalyn Pharma
AVLN
+$19.1M
3
PBLS
Parabilis Medicines Inc
PBLS
+$16M
4
COAG icon
Hemab Therapeutics
COAG
+$15.9M
5
CYTK icon
Cytokinetics
CYTK
+$10.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.7M
2
ACLX icon
Arcellx
ACLX
+$19.5M
3
ELVN icon
Enliven Therapeutics
ELVN
+$15.4M
4
RVMD icon
Revolution Medicines
RVMD
+$15.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACRS icon
26
Aclaris Therapeutics
ACRS
$514M
$22.9M 1.12%
4,330,532
-142,118
-3% -$634K
2015 Q4
42 quarters
MMED icon
27
MiniMed Group Inc
MMED
$5.06B
$22.7M 1.11%
1,520,000
+465,000
+44% +$6.13M
2026 Q1
1 quarter
BSX icon
28
Boston Scientific
BSX
$64B
$22.6M 1.1%
528,500
+13,200
+3% +$717K
2023 Q2
12 quarters
PHVS icon
29
Pharvaris
PHVS
$2.08B
$22.4M 1.09%
648,333
+2,800
+0.4% +$84.7K
2024 Q1
9 quarters
AVLN icon
30
Avalyn Pharma
AVLN
$1.09B
$21.8M 1.07%
+662,918
New +$19.1M
2026 Q2
0 quarters
COAG icon
31
Hemab Therapeutics
COAG
$1.52B
$21.1M 1.03%
+575,432
New +$15.9M
2026 Q2
0 quarters
DYN icon
32
Dyne Therapeutics
DYN
$2.86B
$20.9M 1.02%
942,154
-30,044
-3% -$559K
2024 Q1
9 quarters
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$31.3B
$20.1M 0.98%
66,750
-7,250
-10% -$2.19M
2017 Q2
36 quarters
COGT icon
34
Cogent Biosciences
COGT
$5.12B
$20M 0.97%
515,917
-108,238
-17% -$3.79M
2025 Q2
4 quarters
AGIO icon
35
Agios Pharmaceuticals
AGIO
$1.93B
$19.8M 0.96%
532,563
-266,600
-33% -$8.09M
2019 Q1
29 quarters
NAMS icon
36
NewAmsterdam Pharma
NAMS
$2.46B
$19.7M 0.96%
582,744
-6,050
-1% -$199K
2024 Q3
7 quarters
VERA icon
37
Vera Therapeutics
VERA
$2.06B
$18.3M 0.9%
427,584
-76,001
-15% -$2.83M
2024 Q1
9 quarters
TARS icon
38
Tarsus Pharmaceuticals
TARS
$3.32B
$17.4M 0.85%
277,087
+51,908
+23% +$3.32M
2024 Q4
6 quarters
HTFL icon
39
Heartflow Inc
HTFL
$4.43B
$16.8M 0.82%
573,500
+1,000
+0.2% +$30K
2025 Q3
3 quarters
MBX icon
40
MBX Biosciences
MBX
$2.44B
$16.5M 0.8%
298,218
+10,251
+4% +$358K
2025 Q3
3 quarters
CYTK icon
41
Cytokinetics
CYTK
$8.89B
$16M 0.78%
187,980
+142,616
+314% +$10.2M
2025 Q4
2 quarters
BCAX icon
42
Bicara Therapeutics
BCAX
$1.17B
$15.9M 0.78%
535,286
+46,191
+9% +$1.03M
2024 Q3
7 quarters
PBLS
43
Parabilis Medicines Inc
PBLS
$3.11B
$15.8M 0.77%
+578,028
New +$16M
2026 Q2
0 quarters
ZLAB icon
44
Zai Lab
ZLAB
$2.64B
$15.5M 0.76%
814,707
– –
2017 Q3
35 quarters
DHR icon
45
Danaher
DHR
$163B
$14.5M 0.71%
76,300
+14,800
+24% +$2.69M
2025 Q1
5 quarters
TNGX icon
46
Tango Therapeutics
TNGX
$3.83B
$14.3M 0.7%
456,551
+69,636
+18% +$1.72M
2025 Q4
2 quarters
EVH icon
47
Evolent Health
EVH
$551M
$13.6M 0.66%
2,500,000
-175,000
-7% -$671K
2021 Q1
21 quarters
PTCT icon
48
PTC Therapeutics
PTCT
$5.09B
$13.2M 0.65%
162,298
+500
+0.3% +$36.1K
2025 Q4
2 quarters
MLYS icon
49
Mineralys Therapeutics
MLYS
$1.91B
$13.1M 0.64%
484,951
+45,200
+10% +$1.24M
2025 Q1
5 quarters
ZBIO icon
50
Zenas BioPharma
ZBIO
$1.66B
$12.7M 0.62%
502,077
– –
2024 Q3
7 quarters
1
2
3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rock Springs Capital Management held 116 positions worth $2.05B, up 21% from $1.7B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Rock Springs Capital Management's Q2 2026 filing shows 16 new, 40 increased, 31 reduced and 12 closed positions. Its largest new stake was Avalyn Pharma: 662,918 shares worth $21.8M. The largest sale was argenx, an estimated $37.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Rock Springs Capital Management's largest Q2 2026 buy was Avalyn Pharma: 662,918 shares worth $21.8M.
  • Rock Springs Capital Management added most to Travere Therapeutics in Q2 2026, an estimated $31.1M increase.
  • Rock Springs Capital Management's biggest Q2 2026 reduction was argenx, cutting an estimated $37.7M.
  • Rock Springs Capital Management fully exited Arcellx in Q2 2026, selling an estimated $19.5M.
  • Rock Springs Capital Management's ten largest holdings make up 44% of its $2.05B portfolio in Q2 2026.
  • Rock Springs Capital Management opened 16 new positions and closed 12 in Q2 2026.
  • Rock Springs Capital Management's portfolio value rose 21% quarter-over-quarter to $2.05B.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.